AMEX · Financial Statements

VolitionRX Limited (VNRX) Revenue, Earnings & Financial Statements

$0.19 AMEX: VNRX Market Cap $2.27M

Data as of Nov 17, 2026 close · Statements through the quarter ended Sep 2026 · Source: Financial Modeling Prep (methodology)

VolitionRX Limited most recently reported annual revenue of $2.0M, a net loss of $23.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

VolitionRX Limited: net profit was positive in 0 of 10 reported years; operating margin moved from -93840.2% to -1228.6%, a shift of +92611.6 percentage points; the most recent year shows a net loss of $23.0M.

Income Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Revenue$0$0$0$0$0$0$0$1.0M$1.0M$2.0M
Operating Expenses$12.0M$15.0M$18.0M$16.0M$21.0M$28.0M$32.0M$37.0M$28.0M$23.0M
Operating Profit−$12.0M−$15.0M−$18.0M−$16.0M−$21.0M−$28.0M−$32.0M−$36.0M−$27.0M−$21.0M
Operating Margin———-93840.2%-158176.3%-31469.0%-10372.4%-4641.8%-2190.9%-1228.6%
Other Income$0$0$0$0$1.0M$1.0M$1.0M$0$0−$2.0M
Interest$0$0$0$0$0$0$0$0$0$2.0M
Depreciation$0$1.0M$1.0M$1.0M$1.0M$1.0M$1.0M$1.0M$1.0M$1.0M
Profit Before Tax−$12.0M−$15.0M−$18.0M−$16.0M−$20.0M−$27.0M−$31.0M−$36.0M−$27.0M−$24.0M
Tax rate (%)0.0%1.9%-0.6%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net Profit−$12.0M−$15.0M−$18.0M−$16.0M−$20.0M−$27.0M−$30.0M−$35.0M−$27.0M−$23.0M
EPS−$10.40−$11.20−$11.40−$8.20−$9.00−$10.20−$11.00−$10.00−$6.20−$4.40

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricDec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26Sep '26
Revenue$0$0$0$0$0$0$0$1.0M$0$1.0M$0$2.0M
Operating Expenses$9.0M$9.0M$7.0M$6.0M$6.0M$6.0M$7.0M$6.0M$5.0M$6.0M$5.0M$5.0M
Operating Profit−$9.0M−$8.0M−$7.0M−$6.0M−$6.0M−$6.0M−$6.0M−$5.0M−$5.0M−$5.0M−$4.0M−$3.0M
Operating Margin-3582.6%-4887.9%-1766.2%-1236.8%-3016.5%-2241.1%-1548.6%-813.2%-1058.4%-543.0%-1042.5%-206.6%
Interest$0$0$0$0$0$0$0$1.0M$1.0M$1.0M$1.0M$0
Profit Before Tax−$9.0M−$8.0M−$7.0M−$6.0M−$6.0M−$5.0M−$6.0M−$5.0M−$6.0M−$7.0M−$7.0M−$4.0M
Tax rate (%)0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net Profit−$9.0M−$8.0M−$7.0M−$6.0M−$6.0M−$5.0M−$6.0M−$5.0M−$6.0M−$7.0M−$7.0M−$4.0M
EPS−$2.20−$2.00−$1.69−$1.32−$1.32−$1.12−$1.22−$1.00−$1.05−$0.97−$0.85−$0.21

Over the 10 years reported for VolitionRX Limited, borrowings increased from $1.0M in 2016 to $11.0M in 2025, cash stood at $1.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 0.17 times.

Balance Sheet — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Total Assets$25.0M$15.0M$17.0M$21.0M$26.0M$27.0M$18.0M$28.0M$9.0M$7.0M
Current Assets$22.0M$11.0M$14.0M$18.0M$20.0M$22.0M$12.0M$22.0M$4.0M$2.0M
Cash$22.0M$10.0M$13.0M$17.0M$19.0M$21.0M$11.0M$21.0M$3.0M$1.0M
Inventory$0$0$0$0$0$1.0M$0$0$0$0
Receivables$0$0$0$0$0$0$0$0$0$0
Fixed Assets$2.0M$3.0M$3.0M$3.0M$5.0M$5.0M$6.0M$6.0M$5.0M$5.0M
Capital Work in Progress$0$0$0$0$0$0$0$0$0$0
Investments$0$0$0$0$0$0$0$0$0$0
Other Assets$0$0$0$0$0$0$0$0$0$0
Total Liabilities$4.0M$5.0M$5.0M$7.0M$10.0M$10.0M$21.0M$37.0M$36.0M$42.0M
Current Liabilities$2.0M$2.0M$2.0M$4.0M$6.0M$7.0M$17.0M$9.0M$8.0M$12.0M
Borrowings$1.0M$3.0M$3.0M$4.0M$4.0M$4.0M$5.0M$6.0M$6.0M$11.0M
Other Liabilities$2.0M$2.0M$2.0M$3.0M$5.0M$6.0M$16.0M$31.0M$30.0M$31.0M
Equity$0$0$0$0$0$0$0$0$0$0
Reserves$21.0M$10.0M$12.0M$14.0M$16.0M$18.0M−$3.0M−$8.0M−$25.0M−$34.0M

For VolitionRX Limited, operating cash flow was positive in 0 of 10 reported years; free cash flow in the latest year was negative at $20.0M; free cash flow was positive in 0 of 10 years.

Cash Flow Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Operating Cash Flow−$9.0M−$12.0M−$15.0M−$13.0M−$16.0M−$21.0M−$15.0M−$18.0M−$26.0M−$20.0M
Investing Cash Flow−$1.0M−$3.0M−$1.0M−$1.0M−$4.0M−$2.0M−$3.0M−$2.0M−$1.0M$0
Financing Cash Flow$0$0$0$0$0$0$0$0$0$0
Net Cash Flow$16.0M−$12.0M$3.0M$4.0M$2.0M$1.0M−$10.0M$10.0M−$17.0M−$2.0M
Free Cash Flow−$9.0M−$14.0M−$15.0M−$13.0M−$18.0M−$22.0M−$17.0M−$19.0M−$26.0M−$20.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-0.54
FCF Yield-743.14%
Quick Ratio0.33
Interest Coverage-6.95
Return 1Y-96.71%
Return 3Y-98.51%
Return 5Y-99.74%

VolitionRX Limited (VNRX) financials — frequently asked questions

What is VolitionRX Limited's annual revenue?

VolitionRX Limited (VNRX) reported annual revenue of $2.0M in its most recent fiscal year.

What is VolitionRX Limited's net profit?

VolitionRX Limited (VNRX) reported a net loss of $23.0M in its most recent fiscal year.

What is VNRX EV/EBITDA?

VolitionRX Limited's enterprise value to EBITDA (EV/EBITDA) ratio is -0.54. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.

Revenue and earnings of other Medical - Devices stocks

ABT revenue $44.3BISRG revenue $10.1BMDT revenue $36.4BSYK revenue $25.1BBSX revenue $20.1BEW revenue $6.1BRMD revenue $5.7BDXCM revenue $4.7BPHG revenue $17.8BZBH revenue $8.2BAll Medical - Devices stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksAll stock screens
VNRX Overview VNRX Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.